|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 411 R Street NW |
Address2 |
|
City | Washington |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401105617-51
|
||||||||
|
6. House ID# 447300005
|
TYPE OF REPORT | 8. Year | 2022 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Elizabeth Karan |
Date | 10/20/2022 5:38:25 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Appropriations for the National Breast and Cervical Cancer Early Detection Program
Appropriations for breast cancer research
Appropriations for cancer prevention and control
Policies related to paid family and medical leave
Policies related to development of the Advanced Research Projects Agency for Health
Supplemental appropriations for COVID-19-related relief, the production of monoclonal antibodies, availability of testing, etc
Addition in any reconciliation package of policies related to health insurance coverage and affordability, including permanent extension of Advanced Premium Tax Credits provided by the American Rescue Plan, closing the Medicaid coverage gap, and a cap on out-of-pocket costs for Medicare Part D beneficiaries
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Office of Science & Technology Policy (OSTP), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Johanna |
Gray |
|
Intern, Senator Barack Obama |
|
Elizabeth |
Karan |
|
|
|
Leslie |
Brady |
|
Health Policy Advisor/Legislative Assistant, Rep. Brian Higgins |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
Access to Breast Cancer Diagnosis (ABCD) Act (S. 1067/ H.R. 5769)
Metastatic Breast Cancer Access to Care Act (S. 1312 / HR 3182)
Cancer Drug Coverage Parity Act (HR 4385)
Protecting Access to Lifesaving Screening (PALS) Act(HR 4612/S.2412)
Safe Step Act (H.R. 2163/S. 464)
The Closing Health Coverage Gaps for Public Servants Act (H.R. 7045/S. 3796)
Implementation of the Affordable Care Act
Implementation of the No Surprises Act
Policies related to insurance coverage and COVID-19
Junk Plan Accountability and Disclosure Act (S. 1002)
No Junk Plans Act (S. 942)
HELP Copays Act (H.R.5801), accumulator adjustor issues
Cancer survivorship issues
Issues related to prescription drug affordability for patients
Administrative actions necessary to reduce out-of-pocket costs for medical-necessary diagnostic breast imaging
Policies regarding White House Cancer Moonshot implementation
Issues related to regulation of short-term limited duration plans
H.R. 5376 - Inflation Reduction Act of 2022; a budget reconciliation bill which included provisions to continue subsidies on private insurance premiums, address out of pocket costs in Medicare Part D, and more
Comments on future rulemaking for the 2024 Notice on Benefit and Payment Parameters
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Internal Revenue Service (IRS), Labor - Dept of (DOL), Office of Personnel Management (OPM), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Johanna |
Gray |
|
Intern, Senator Barack Obama |
|
Elizabeth |
Karan |
|
|
|
Leslie |
Brady |
|
Health Policy Advisor/Legislative Assistant, Rep. Brian Higgins |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Metastatic Breast Cancer Access to Care Act (S. 1312 / HR 3182)
Multi-Cancer Early Detection Screening Coverage Act (HR 1946/S 1873)
Lymphedema Treatment Act (HR 3630/ S 1315)
Breast Cancer Patient Equity Act (HR 3087/S 2051)
Reducing Hereditary Cancer Act of 2021 (HR 4110)
CONNECT for Health Act (S.1512/ H.R. 2903)
Improving Seniors' Timely Access to Care Act (H.R.3173)
Comprehensive Breast Reconstruction Act of 2021 (H.R. 469)
Seniors Prescription Drug Relief Act (S.2327)
Medicare coverage policy for breast cancer treatments and services
Radiation Oncology Alternative Payment Model
Telehealth
Policies related to funding, state incentives, and federal efforts for Medicaid expansion
Issues related to 1115 and 1332 of the Social Security Act; policies related to work requirements, reinsurance and block grants in Medicaid
Policies related to Medicare coverage for pharmacy services and the Equitable Community Access to Pharmacist Services Act (H.R.7213)
Issues related to the upcoming Notice on Benefit and Payment Parameters for FY2024
Medicare coverage policy for drugs and drug pricing
H.R. 5376 - Inflation Reduction Act of 2022; a budget reconciliation bill which included provisions to continue subsidies on private insurance premiums, address out of pocket costs in Medicare Part D, and more
Comments in response to CMS Proposed Rule on CY 2023 Medicare Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System (CMS 1772-P)
Comments in response to CMS Request for Information on Medicare Advantage (CMS-4203-NC)
Comments in response to CY2023 Medicare Physician Fee Schedule (CMS-1770-P)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Johanna |
Gray |
|
Intern, Senator Barack Obama |
|
Elizabeth |
Karan |
|
|
|
Leslie |
Brady |
|
Health Policy Advisor/Legislative Assistant, Rep. Brian Higgins |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
Breast cancer research at the Department of Defense
H.R. 7900 - National Defense Authorization Act for Fiscal Year 2023; a bill to authorize Department of Defense activities and programs for FY 2023
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Johanna |
Gray |
|
Intern, Senator Barack Obama |
|
Elizabeth |
Karan |
|
|
|
Leslie |
Brady |
|
Health Policy Advisor/Legislative Assistant, Rep. Brian Higgins |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Health disparities
Access to clinical trials for underrepresented populations
Improving Social Determinants of Health Act (S.104/H.R.379)
Comprehensive Breast Reconstruction Act of 2021 (H.R. 469)
DIVERSE Trials Act (H.R. 5030/S. 2706)
Diverse and Equitable Participation in Clinical Trials (DEPICT) Act (H.R.6584); a bill to direct the Commissioner of Food and Drugs to amend certain regulations to increase clinical trial diversity, and for other purposes
CURES 2.0 Act (H.R. 6000)
Policies related to cancer survivorship
Policies related to medications access in during emergencies
Polices related to PBM and drug cost transparency
Policies related to COVID-19 vaccination distribution
Policies impacting immunocompromised people, including COVID-19 vaccination and monoclonal antibody distribution
Policies related to reducing the cost of cancer treatment for patients
Policies related to decline in breast cancer screenings during the COVID-19 pandemic
Policies related to genetic counseling and screening
Policies related to reauthorization of user fees at the Food and Drug Administration (H.R. 7667/ S. 4348)
H.R. 7845 NIH Clinical Trial Diversity Act; a bill to direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes.
H.R. 8185/S. 4440 - Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; a bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2023 through 2027
Advanced Research Project Agency-Health Act (H.R.5585)
Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT) Pandemics Act (S.3799)
Policies related to the implementation of the Breast Density and Mammography Reporting Act of 2017
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Johanna |
Gray |
|
Intern, Senator Barack Obama |
|
Elizabeth |
Karan |
|
|
|
Leslie |
Brady |
|
Health Policy Advisor/Legislative Assistant, Rep. Brian Higgins |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
Making Advances in Mammography and Medical Options for Veterans Act (S.2533/H.R.4794)
H.R. 4571/S. 2102 - Supporting Expanded Review for Veterans in Combat Environments (SERVICE) Act of 2021
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Elizabeth |
Karan |
|
|
|
Johanna |
Gray |
|
Intern, Senator Barack Obama
|
|
Leslie |
Brady |
|
Health Policy Advisor/Legislative Assistant, Rep. Brian Higgins |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |